Table 2.
All reviews N = 98 | Cochrane reviews N = 57 | Non-Cochrane reviews N = 41 | Tobacco use N = 49 | HIV infection N = 49 | |
---|---|---|---|---|---|
Setting and centres | |||||
Setting of recruitment | 45 (46) | 33 (58) | 12 (29) | 24 (49) | 21 (43) |
Number of centres | 21 (21) | 19 (33) | 2 (5) | 15 (31) | 6 (12) |
Country where the study took place | 62 (63) | 41 (72) | 21 (51) | 29 (59) | 33 (67) |
Recruitment | |||||
Method | 18 (18) | 18 (32) | 0 | 15 (31) | 3 (6) |
Participants | |||||
Inclusion criteria | 16 (16) | 13 (23) | 3 (7) | 5 (10) | 11 (22) |
Exclusion criteria | 13 (13) | 11 (19) | 2 (5) | 4 (8) | 9 (18) |
Baseline characteristics of participants | 59 (60) | 42 (74) | 17 (41) | 29 (59) | 30 (61) |
Age | 47 (48) | 35 (61) | 12 (29) | 26 (53) | 21 (43) |
Mean or median only | 39 (40) | 29 (51) | 10 (24) | 21 (43) | 18 (37) |
Mean (SD) or median (IQR) | 3 (3) | 3 (5) | 0 | 0 | 3 (6) |
Minimum and maximum value only | 17 (17) | 12 (21) | 5 (12) | 8 (16) | 9 (18) |
Sex | 46 (47) | 33 (58) | 13 (32) | 22 (45) | 24 (49) |
Ethnicity | 9 (9) | 4 (3) | 5 (12) | 2 (4) | 7 (14) |
Socioeconomic status | 1 (1) | 1 (2.0) | 0 | 0 | 1 (2) |
Co-morbidities | 0 | 0 | 0 | 0 | 0 |
Associated treatments | 0 | 0 | 0 | 0 | 0 |
Treatment | |||||
Duration of treatment | 61 (62) | 40 (70) | 21 (51) | 35 (71) | 26 (53) |
Intensity/dose of treatment | 64 (65) | 44 (77) | 20 (49) | 34 (69) | 30 (61) |
Delivery format of treatment | 72 (73) | 49 (86) | 23 (56) | 37 (75) | 35 (71) |
Treatment timing | 52 (53) | 40 (70) | 12 (29) | 30 (61) | 22 (45) |
Compliance of participants | 3 (3) | 0 | 3 (7) | 0 | 3 (6) |
Outcome assessment | |||||
Primary outcome | 67 (68) | 52 (91) | 15 (37) | 22 (45) | 35 (71) |
Adverse events | 5 (5) | 3 (5) | 2 (5) | 2 (4) | 3 (6) |
Follow up | |||||
Length of follow-up | 34 (35) | 17 (30) | 17 (41) | 20 (41) | 14 (29) |
Number of visits | 13 (13) | 12 (21) | 1 (2) | 9 (18) | 4 (8) |